Webinar: Debunking the myths around investing in medical cannabis
Debunking the myths around investing in medical cannabis – From the experts, New Frontier Data and Rize ETF.
Medical cannabis has quickly become one of the most socially disruptive phenomena of the new millennium, and it is showing no signs of slowing.
It is estimated that, by 2026, the global medical cannabis market will reach a value of $148.35 Billion (New Frontier Data, 2019). However, to many investors, this is still a complicated area that elicits questions around awareness, market structure, therapeutics, and of course legality and regulation. In this webinar, Giadha Aguirre de Carcer, Chief Executive Officer at New Frontier Data, joins us to explain how the medical cannabis movement is going global, and the investment opportunities it is unearthing in its wake. We also deep-dive into the legal and regulatory considerations for UK and European investors who are looking to invest in this promising sector.
Recorded on May 6th, 2020.
FLWR: The Rize Medical Cannabis and Life Sciences UCITS ETF seeks to track the Foxberry Medical Cannabis & Life Sciences Index. The objective of the Index is to provide exposure to companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. The Index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market.
Capital at Risk Warning: An investment in the Fund(s) involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. The Funds may be registered or otherwise approved for distribution to the public in one or more European jurisdictions. Investors should continue to consider the terms of investment in any Fund (or Share Class thereof) carefully and seek professional investment advice before taking any decision to invest in such Fund (or Share Class thereof).